CL2021003280A1 - Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal - Google Patents
Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renalInfo
- Publication number
- CL2021003280A1 CL2021003280A1 CL2021003280A CL2021003280A CL2021003280A1 CL 2021003280 A1 CL2021003280 A1 CL 2021003280A1 CL 2021003280 A CL2021003280 A CL 2021003280A CL 2021003280 A CL2021003280 A CL 2021003280A CL 2021003280 A1 CL2021003280 A1 CL 2021003280A1
- Authority
- CL
- Chile
- Prior art keywords
- renal failure
- fabry disease
- patients
- methods
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se proporcionan métodos para al tratamiento de la enfermedad de Fabry en un paciente que tiene insuficiencia renal. Determinados métodos comprenden administrar al paciente de aproximadamente 100 mg a aproximadamente 300 mg de equivalente de base libre de migalastat o sal del mismo a una frecuencia mayor de una vez cada dos días, tal como una vez cada cuatro o siete días. Determinados métodos comprenden medir la liso-Gb3 y/o el migalastat en una o más muestras de plasma del paciente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962859904P | 2019-06-11 | 2019-06-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021003280A1 true CL2021003280A1 (es) | 2022-10-07 |
Family
ID=71950725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021003280A CL2021003280A1 (es) | 2019-06-11 | 2021-12-09 | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220313670A1 (es) |
EP (1) | EP3982962A1 (es) |
JP (1) | JP2022536687A (es) |
KR (1) | KR20220019796A (es) |
CN (1) | CN114423427A (es) |
AR (1) | AR120055A1 (es) |
AU (1) | AU2020291002A1 (es) |
BR (1) | BR112021024886A2 (es) |
CA (1) | CA3141226A1 (es) |
CL (1) | CL2021003280A1 (es) |
EA (1) | EA202290024A1 (es) |
IL (1) | IL288677A (es) |
MX (1) | MX2021015352A (es) |
TW (1) | TW202112372A (es) |
WO (1) | WO2020252129A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2652553C (en) | 2006-05-16 | 2020-08-18 | Amicus Therapeutics, Inc. | Use of 1-deoxygalactonojirimycin or a salt thereof in the treatment of fabry disease |
ES2541933T3 (es) | 2008-02-12 | 2015-07-28 | Amicus Therapeutics, Inc. | Método para predecir la respuesta al tratamiento farmacológico con chaperona de enfermedades |
US10251873B2 (en) | 2017-05-30 | 2019-04-09 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
AU2020327019A1 (en) | 2019-08-07 | 2022-03-03 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
US20100113517A1 (en) | 2007-03-30 | 2010-05-06 | Amicus Therapeutics, Inc. | Method for the treatment of fabry disease using pharmacological chaperones |
MX2009011473A (es) * | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
ES2541933T3 (es) | 2008-02-12 | 2015-07-28 | Amicus Therapeutics, Inc. | Método para predecir la respuesta al tratamiento farmacológico con chaperona de enfermedades |
JP2014528901A (ja) * | 2011-03-11 | 2014-10-30 | アミカス セラピューティックス インコーポレイテッド | ファブリー病の治療用投薬レジメン |
US20190183869A1 (en) * | 2016-07-19 | 2019-06-20 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
KR20190103320A (ko) * | 2017-01-05 | 2019-09-04 | 프로탈릭스 리미티드 | 안정화된 알파-갈락토시다제를 이용하는 파브리의 치료를 위한 치료적 요법 |
US10251873B2 (en) * | 2017-05-30 | 2019-04-09 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
AR111971A1 (es) * | 2017-05-30 | 2019-09-04 | Amicus Therapeutics Inc | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal |
-
2020
- 2020-06-11 CN CN202080042938.3A patent/CN114423427A/zh active Pending
- 2020-06-11 WO PCT/US2020/037174 patent/WO2020252129A1/en unknown
- 2020-06-11 MX MX2021015352A patent/MX2021015352A/es unknown
- 2020-06-11 US US17/618,277 patent/US20220313670A1/en active Pending
- 2020-06-11 JP JP2021573404A patent/JP2022536687A/ja active Pending
- 2020-06-11 AU AU2020291002A patent/AU2020291002A1/en active Pending
- 2020-06-11 EA EA202290024A patent/EA202290024A1/ru unknown
- 2020-06-11 BR BR112021024886A patent/BR112021024886A2/pt unknown
- 2020-06-11 KR KR1020227000878A patent/KR20220019796A/ko unknown
- 2020-06-11 CA CA3141226A patent/CA3141226A1/en active Pending
- 2020-06-11 TW TW109119640A patent/TW202112372A/zh unknown
- 2020-06-11 AR ARP200101648A patent/AR120055A1/es unknown
- 2020-06-11 EP EP20751716.0A patent/EP3982962A1/en active Pending
-
2021
- 2021-12-05 IL IL288677A patent/IL288677A/en unknown
- 2021-12-09 CL CL2021003280A patent/CL2021003280A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020291002A1 (en) | 2022-01-06 |
US20220313670A1 (en) | 2022-10-06 |
IL288677A (en) | 2022-02-01 |
CN114423427A (zh) | 2022-04-29 |
JP2022536687A (ja) | 2022-08-18 |
EP3982962A1 (en) | 2022-04-20 |
TW202112372A (zh) | 2021-04-01 |
WO2020252129A1 (en) | 2020-12-17 |
KR20220019796A (ko) | 2022-02-17 |
CA3141226A1 (en) | 2020-12-17 |
EA202290024A1 (ru) | 2022-03-14 |
AR120055A1 (es) | 2022-02-02 |
BR112021024886A2 (pt) | 2022-01-25 |
MX2021015352A (es) | 2022-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021003280A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
CO2018006358A2 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
JOP20200156A1 (ar) | إيسكيتامين لعلاج الاكتئاب | |
CO2022002638A2 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla | |
EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
MX2023005628A (es) | Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry. | |
AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
CO2022005113A2 (es) | Métodos de tratamiento para modificar la hemodinámica | |
EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
AR111971A1 (es) | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal | |
EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
EP4245366A3 (en) | Migalastat for treating fabry patients having renal impairment | |
EA202190294A1 (ru) | Комбинированная терапия для лечения рака | |
UA113183C2 (xx) | Спосіб лікування адикції | |
EA201992869A1 (ru) | Способы лечения пациентов с болезнью фабри, у которых имеется почечная недостаточность | |
AR109102A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
AR122298A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla | |
UA109966C2 (uk) | Спосіб лікування латентної ішемічної хвороби серця у хворих на бронхіальну астму | |
EA201991119A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения |